Genome Insight specializes in advanced genomic testing technologies aimed at enhancing the diagnosis and treatment of cancer and rare diseases. Their flagship products, CancerVision and RareVision, utilize whole genome sequencing to provide comprehensive insights into a patient's genetic makeup. CancerVision is designed specifically for patients with solid tumor cancers, offering extensive analysis and actionable treatment options, while RareVision focuses on diagnosing rare diseases by identifying relevant genetic variants. Both tests leverage a proprietary bioinformatics platform that ensures a thorough analysis of genomic data, translating complex genetic information into user-friendly reports that empower patients and healthcare providers to make informed decisions.

The company's approach to whole genome sequencing stands out due to its ability to detect complicated mutations that are often missed by standard panel tests and whole exome sequencing. By analyzing over 99% of a person's genetic material, Genome Insight's technology provides a broader and more detailed view of genetic variations, which can lead to additional diagnoses and better treatment strategies. Their commitment to precision health is further supported by services such as genetic counseling and connections to clinical trials, ensuring that patients receive not only insights but also actionable steps for their health journey.

United States

Genome Insight is a biotechnology company that specializes in whole genome sequencing for cancer and rare diseases, aiming to transform disease treatment with advanced genetic analysis.

Genome Insight

Company Details